Lilly's Leap Tests Investors' Faith In Solanezumab
This article was originally published in Scrip
Eli Lilly & Co. concedes that its revised primary endpoint for the ongoing Phase III clinical trial testing solanezumab in mild Alzheimer's patients goes against US FDA and European Medicines Agency (EMA) requirements, but the company is "hopeful" the change still will support regulatory approvals.
You may also be interested in...
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.